Allara, Elias

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,097

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchEvolution and Genetic Dynamics

Cited by 1,006

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Twohig, K. A., Nyberg, T., Zaidi, A., Thelwall, S., Sinnathamby, M. A., Aliabadi, S., Seaman, S. R., Harris, R. J., Hope, R., Lopez-Bernal, J., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 803

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 785

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 728

A robust and efficient method for Mendelian randomization with hundreds of genetic variants

Burgess, S., Foley, C. N., Allara, E., Staley, J. R., & Howson, J. M. M. (2020) · Nature Communications

Genetic Associations and EpidemiologyAdvanced Causal Inference Techniques

Cited by 681

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Pinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., Falconer, A., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 626

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., et al. (2021) · The Lancet Public Health

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 304

Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition

Kettunen, J., Holmes, M. V., Allara, E., Anufrieva, O., Ohukainen, P., Oliver-Williams, C., Wang, Q., Tillin, T., Hughes, A. D., Kähönen, M., et al. (2019) · PLOS Biology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 47

Association of shorter leucocyte telomere length with risk of frailty

Bountziouka, V., Nelson, C. P., Codd, V., Wang, Q., Musicha, C., Allara, E., Kaptoge, S., Di Angelantonio, E., Butterworth, A. S., Thompson, J. R., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle

Frailty in Older AdultsTelomeres, Telomerase, and Senescence

Cited by 36